Gawrieh and colleagues examined 534 patients diagnosed with NAFLD who had normal ALT levels and found that 19% had NASH with clinically significant or advanced fibrosis (F2-F3), and 7% had cirrhosis, with T2D emerging as the strongest predictor of NASH [5]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.